Copyright
©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2354-2364
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2354
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2354
n = 40 patients | |
Age at the time of inclusion, mean ± SD (yr) | 34 .0 ± 13.6 |
Disease duration, median (IQR) (yr) | 4 (0.8-11.3) |
Female gender, n (%) | 21 (52.5) |
Current smokers, n (%) | 15 (37.5) |
Prior bowel resection, n (%) | 7 (17.5) |
Montreal classification | |
Location | |
L1, n (%) | 18 (45.0) |
L2, n (%) | 3 (7.5) |
L3, n (%) | 19 (47.5) |
Behaviour | |
B1, n (%) | 13 (32.5) |
B2, n (%) | 16 (40.0) |
B3, n (%) | 11 (27.5) |
Perianal lesions, n (%) | 7 (17.5) |
Anti-TNF-naïve patients, n (%) | 24 (60.0) |
Type of anti-TNF | |
Infliximab, n (%) | 16 (40.0) |
Adalimumab, n (%) | 24 (60.0) |
Concomitant medications | |
Immunosuppressive therapies, n (%) | 21 (52.5) |
Steroids, n (%) | 7 (17.5) |
Faecal calprotectin level at baseline, median (IQR) (µg/g) | 1010.5 (357.8-1800.0) |
CRP level at baseline, median (IQR) (mg/L) | 13.2 (5.2-25.9) |
Endpoints | Sensitivity | Specificity | PPV | NPV | LR+ | LR- | Accuracy |
CDAI < 150 | 84.6% (56.3-96.6) | 55.6% (37.3-72.4) | 47.8% (27.4-68.2) | 88.2% (72.9-100.0) | 1.904 (1.177-3.081) | 0.277 (0.074-1.035) | 60.5% (50.2-79.8) |
CRP ≤ 2.9 mg/L | 92.3% (64.2-100.0) | 74.1% (55.0-86.9) | 63.2% (41.5-84.8) | 95.2% (86.1-100.0) | 3.560 (1.846-6.865) | 0.104 (0.016-0.692) | 80.0% (67.6-92.4) |
CDAI < 150 and CRP ≤ 2.9 mg/L | 76.9% (48.9-92.2) | 85.2% (66.7-94.6) | 71.4% (47.8-95.1) | 88.5% (76.2-100.0) | 5.192 (2.004-13.456) | 0.271 (0.099-0.740) | 82.5% (70.7-94.3) |
Fcal < 300 µg/g | 84.6% (56.3-96.6) | 77.8% (58.8-89.6) | 64.7% (42.0-87.4) | 91.3% (79.8-100%) | 3.808 (1.812-8.003) | 0.198 (0.054-0.719) | 80.0% (67.6-92.4) |
Fcal improvement | 76.9% (48.9-92.2) | 92.6% (75.3-98.9) | 83.3% (62.2-100.0) | 89.3% (77.8-100.0) | 10.385 (2.648-40.721) | 0.249 (0.092-0.676) | 87.5% (77.3-97.7) |
CDAI < 150 and Fcal improvement | 69.2% (42.0-87.4) | 96.3% (79.9-100.0) | 90.0% (71.4-100.0) | 86.7% (74.5-98.8) | 18.692 (2.640-132.328) | 0.320 (0.141-0.725) | 87.5% (77.3-97.7) |
CDAI < 150 and CRP ≤ 2.9 mg/L and Fcal improvement | 69.2% (42.0-87.4) | 100.0% (84.9-100.0) | 100.0% (100.0-100.0) | 87.1% (75.3-98.9) | NA | 0.308 (0.136-0.695) | 90.0% (80.7-99.3) |
- Citation: Sollelis E, Quinard RM, Bouguen G, Goutte M, Goutorbe F, Bouvier D, Pereira B, Bommelaer G, Buisson A. Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease. World J Gastroenterol 2019; 25(19): 2354-2364
- URL: https://www.wjgnet.com/1007-9327/full/v25/i19/2354.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i19.2354